Cargando…
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients
There is a lack of studies comparing the risk of cardio-cerebrovascular disease between angiotensin receptor blockers (ARBs) of different half-lives. We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659604/ https://www.ncbi.nlm.nih.gov/pubmed/37986329 http://dx.doi.org/10.1097/MD.0000000000036098 |
_version_ | 1785148346065747968 |
---|---|
author | Yoo, Yung-Geun Lim, Min-Jung Kim, Jin-Seob Jeong, Han-Eol Ko, HeeJoo Shin, Ju-Young |
author_facet | Yoo, Yung-Geun Lim, Min-Jung Kim, Jin-Seob Jeong, Han-Eol Ko, HeeJoo Shin, Ju-Young |
author_sort | Yoo, Yung-Geun |
collection | PubMed |
description | There is a lack of studies comparing the risk of cardio-cerebrovascular disease between angiotensin receptor blockers (ARBs) of different half-lives. We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension. To establish a cohort exposed to valsartan, losartan, irbesartan, or telmisartan, we performed propensity score (PS) matching and used an as-treated approach to evaluate exposure. The Cox regression model was employed to calculate hazard ratios, which were based on the incidence rate for each newly occurring event of MI, heart failure, or cerebrovascular disease. These hazard ratios were calculated to compare the risk of MI, heart failure, and cerebrovascular disease associated with valsartan, losartan, and irbesartan in comparison to telmisartan. A PS-matched cohort of 148,229 patients was established for each of valsartan, losartan, irbesartan, or telmisartan. The matched cohort analysis showed that the adjusted hazard ratio (aHRs, 95% confidence interval) for MI was higher for valsartan use (1.39, 1.33–1.45) and losartan use (1.10, 1.05–1.15) but lower for irbesartan use (0.90, 0.86–0.94) compared with the reference (telmisartan). The aHRs for HF were not different among these ARBs (angiotensin receptor blockers). The aHR for cerebrovascular disease was lower for valsartan use (0.85, 0.83–0.87) and losartan use (0.80, 0.78–0.82) but higher for irbesartan use (1.11, 1.09–1.13) compared with the reference. We found differences in the risk of MI and cerebrovascular disease with the use of different ARBs compared to telmisartan use. Valsartan, and losartan with a short half-life, which showed a higher risk of MI, had a lower risk of cerebrovascular disease. Conversely, irbesartan with a long half-life, which showed a lower risk of MI, had a higher risk of cerebrovascular disease. |
format | Online Article Text |
id | pubmed-10659604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106596042023-11-17 Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients Yoo, Yung-Geun Lim, Min-Jung Kim, Jin-Seob Jeong, Han-Eol Ko, HeeJoo Shin, Ju-Young Medicine (Baltimore) 3400 There is a lack of studies comparing the risk of cardio-cerebrovascular disease between angiotensin receptor blockers (ARBs) of different half-lives. We aimed to compare the risks of myocardial infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan with different half-lives in a national claim-based retrospective cohort of patients aged ≥ 40 years with hypertension. To establish a cohort exposed to valsartan, losartan, irbesartan, or telmisartan, we performed propensity score (PS) matching and used an as-treated approach to evaluate exposure. The Cox regression model was employed to calculate hazard ratios, which were based on the incidence rate for each newly occurring event of MI, heart failure, or cerebrovascular disease. These hazard ratios were calculated to compare the risk of MI, heart failure, and cerebrovascular disease associated with valsartan, losartan, and irbesartan in comparison to telmisartan. A PS-matched cohort of 148,229 patients was established for each of valsartan, losartan, irbesartan, or telmisartan. The matched cohort analysis showed that the adjusted hazard ratio (aHRs, 95% confidence interval) for MI was higher for valsartan use (1.39, 1.33–1.45) and losartan use (1.10, 1.05–1.15) but lower for irbesartan use (0.90, 0.86–0.94) compared with the reference (telmisartan). The aHRs for HF were not different among these ARBs (angiotensin receptor blockers). The aHR for cerebrovascular disease was lower for valsartan use (0.85, 0.83–0.87) and losartan use (0.80, 0.78–0.82) but higher for irbesartan use (1.11, 1.09–1.13) compared with the reference. We found differences in the risk of MI and cerebrovascular disease with the use of different ARBs compared to telmisartan use. Valsartan, and losartan with a short half-life, which showed a higher risk of MI, had a lower risk of cerebrovascular disease. Conversely, irbesartan with a long half-life, which showed a lower risk of MI, had a higher risk of cerebrovascular disease. Lippincott Williams & Wilkins 2023-11-17 /pmc/articles/PMC10659604/ /pubmed/37986329 http://dx.doi.org/10.1097/MD.0000000000036098 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 3400 Yoo, Yung-Geun Lim, Min-Jung Kim, Jin-Seob Jeong, Han-Eol Ko, HeeJoo Shin, Ju-Young Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title_full | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title_fullStr | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title_full_unstemmed | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title_short | Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
title_sort | risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients |
topic | 3400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659604/ https://www.ncbi.nlm.nih.gov/pubmed/37986329 http://dx.doi.org/10.1097/MD.0000000000036098 |
work_keys_str_mv | AT yooyunggeun riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients AT limminjung riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients AT kimjinseob riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients AT jeonghaneol riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients AT koheejoo riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients AT shinjuyoung riskofmyocardialinfarctionheartfailureandcerebrovasculardiseasewiththeuseofvalsartanlosartanirbesartanandtelmisartaninpatients |